Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648182 | 1.00 | MTNR1A (0.44) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL5072835 | 1.00 | MTNR1A (0.44) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL387761 | 0.98 | MTNR1A (0.43) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL7584602 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL4659375 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL4659374 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL187459 | 0.85 | SRC (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL10600977 | 0.85 | CA2 (0.44) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL14247549 | 0.85 | SRC (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 | |
| SCHEMBL5142053 | 0.85 | SRC (0.46) | MTNR1AMTNR1BCES1CES2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114667823-B | Method for accelerating germination of tomato seeds by using magnetic field | 安徽省富美四季农业科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-115785067-A | Preparation method of impurity compound of esomeprazole thioether | 北京京卫燕康药物研究所有限公司 | 2023-03-14 | — | — | CN | claimed |
| WO-2018204829-A1 | METHODS FOR PREVENTING NEURAL TUBE DEFECTS IN DIABETIC PREGNANCY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-11-08 | — | — | WO | claimed |
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| EP-1747059-A1 | PERVAPORATION COMPOSITE MEMBRANES | McMaster University (CA) | 2007-01-31 | — | — | EP | claimed |
| US-20060000778-A1 | high-performance membrane designed for the selective removal of a polar fluid (water) from less polar fluids (organic solvents), by a pervaporation using a composite membrane contaiing ultrafiltration membrane as support ( e.g. cellulose acetate) and a crosslinked copolymer of anionic, cationic monomers | MCMASTER UNIVERSITY (CA) | 2006-01-05 | — | — | US | claimed |
| WO-2005102503-A1 | PERVAPORATION COMPOSITE MEMBRANES | MCMASTER UNIVERSITY (CA) | 2005-11-03 | — | — | WO | claimed |
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0592552-B1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | DU PONT (US) | 1997-05-28 | — | — | EP | claimed |
| EP-0739333-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-30 | — | — | EP | claimed |
| US-5559267-A | ENANTIOMORPHS, STEREOCHEMICAL CONTROL AND ASSYMETRIC INDUCTION, HYDROGENATION OF UNSATURATED ESTERS, COORDINATION CATALYSTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-24 | — | — | US | claimed |
| US-5510507-A | COORDINATION CATALYSTS; EFFICIENT ENANTIOSELECTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | claimed |
| WO-1995018787-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0592552-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES. | DU PONT (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1993001199-A1 | CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-01-21 | — | — | WO | claimed |
| EP-0252216-B1 | MICROBIOLOGICALLY PRODUCED ALPHA-ACETYLAMINO CINNAMIC ACID ACYLASE, METHOD OF ITS PRODUCTION AND ITS USE | Degussa Aktiengesellschaft (DE) | 1992-01-29 | — | — | EP | claimed |
| EP-0077099-A2 | Process for preparing amino acids and their esters | ANIC S.p.A. (IT) | 1983-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | MTNR1A 3709/4885MTNR1B 3386/4885CES1 719/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | MTNR1A 3709/4885MTNR1B 3386/4885CES1 719/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | MTNR1A 3709/4885MTNR1B 3386/4885CES1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.